Ensysce Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ensysce Biosciences
ENSC Stock  USD 0.44  0.17  27.87%   
Ensysce Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ensysce Biosciences' valuation are provided below:
Gross Profit
-6.1 M
Profit Margin
(2.44)
Market Capitalization
2.2 M
Revenue
4.5 M
Earnings Share
(6.35)
We have found one hundred twenty available fundamental signals for Ensysce Biosciences, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of Ensysce Biosciences' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road.

Ensysce Biosciences Total Revenue

6.29 Million

Check Ensysce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ensysce Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 373.2 K, Interest Income of 1.1 M or Interest Expense of 1.6 M, as well as many indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 16.31 or PTB Ratio of 3.62. Ensysce financial statements analysis is a perfect complement when working with Ensysce Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Ensysce Stock
Check out the analysis of Ensysce Biosciences Correlation against competitors.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

Ensysce Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.8 M5 M121.3 M
Slightly volatile
Other Current Liabilities599.2 K630.7 K781.9 K
Slightly volatile
Total Current Liabilities2.4 M2.5 M2.8 M
Slightly volatile
Cash3.4 M4 M2.8 M
Slightly volatile
Non Current Assets Total215.9 K227.3 K117.7 M
Slightly volatile
Cash And Short Term Investments3.4 M4 M2.8 M
Slightly volatile
Common Stock Shares Outstanding1.6 M1.6 M3.6 M
Slightly volatile
Short Term Investments4.2 T4 T1.3 T
Slightly volatile
Liabilities And Stockholders Equity4.8 M5 M121.3 M
Slightly volatile
Non Current Liabilities Total8.6 K9.1 K5.1 M
Slightly volatile
Capital Surpluse129.5 M123.3 M45.6 M
Slightly volatile
Other Current Assets1.2 M2 M803.3 K
Slightly volatile
Other Stockholder Equity95.1 M153.2 M57.4 M
Slightly volatile
Total Liabilities1.9 M2 M7.4 M
Pretty Stable
Total Current Assets4.7 M6.1 M3.6 M
Slightly volatile
Common Stock11612210.7 M
Very volatile
Warrants149.4 M163.1 M184.2 M
Slightly volatile
Accounts Payable1.5 M1.6 M926.9 K
Slightly volatile
Net Receivables171.2 K111.7 K198.4 K
Very volatile
Common Stock Total Equity63.9 K60.9 K23.3 K
Slightly volatile
Deferred Long Term Liabilities1.4 K1.6 K1.7 K
Slightly volatile
Non Current Liabilities Other298.6 K314.3 K5 M
Slightly volatile
Short and Long Term Debt Total257.9 K271.5 K3.5 M
Very volatile
Long Term Debt153.1 K161.2 K684.1 K
Very volatile
Short and Long Term Debt257.9 K271.5 K3.8 M
Slightly volatile
Capital Stock1161221.2 K
Slightly volatile
Other Liabilities2.9 M3.3 M3.6 M
Slightly volatile
Cash And Equivalents2.7 M2.8 M9.5 M
Slightly volatile

Ensysce Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision373.2 K281.2 K177.4 K
Slightly volatile
Interest Income1.1 M1.2 M849.8 K
Slightly volatile
Other Operating Expenses10.9 M13.7 M6.2 M
Slightly volatile
Cost Of Revenue6.2 M8.3 M3.9 M
Slightly volatile
Non Operating Income Net Other5.1 M6.8 M4.6 M
Slightly volatile
Selling General Administrative5.8 M4.2 M6.8 M
Very volatile
Selling And Marketing Expenses2.9 M3.2 M3.5 M
Slightly volatile
Research Development8.6 M8.3 M5.6 M
Slightly volatile

Ensysce Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow4.2 T4 T691.7 B
Slightly volatile
Begin Period Cash Flow1.4 T1.3 T221.9 B
Slightly volatile
Stock Based Compensation133.7 B127.3 B21.9 B
Slightly volatile
Dividends Paid247.9 M261 M94.5 B
Pretty Stable
Issuance Of Capital Stock1.4 M1.5 M6.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.983.1479.2 K
Slightly volatile
Dividend Yield16.3118.3520.0326
Slightly volatile
Days Sales Outstanding9.510.031.4488
Slightly volatile
Average Payables1.3 M1.5 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue20.1 K19.1 K3.6 K
Slightly volatile
EV To Sales2.312.4379.2 K
Slightly volatile
Payables Turnover2.974.795.0972
Slightly volatile
Sales General And Administrative To Revenue0.991.043.1082
Slightly volatile
Research And Ddevelopement To Revenue2.271.252.2294
Pretty Stable
Capex To Revenue0.00.00.0
Slightly volatile
Cash Per Share1.711.810.156
Pretty Stable
Days Payables Outstanding74.9678.91227.1 K
Pretty Stable
Income Quality887.7 K845.4 K157.2 K
Slightly volatile
Current Ratio3.292.787.8432
Slightly volatile
Receivables Turnover39.6737.7815.8257
Slightly volatile
Capex Per Share0.00.00.0
Slightly volatile
Average Receivables127.5 K198.8 K139.4 K
Slightly volatile
Revenue Per Share3.263.434.1464
Slightly volatile
Interest Debt Per Share1.01.0514.9723
Pretty Stable
Debt To Assets0.05890.0623.3203
Slightly volatile
Days Of Payables Outstanding74.9678.91227.1 K
Pretty Stable
Quick Ratio3.292.787.8448
Slightly volatile
Cash Ratio2.781.826.9695
Slightly volatile
Days Of Sales Outstanding9.510.031.4488
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9824
Slightly volatile
Fixed Asset Turnover2.0E-42.0E-44.5 K
Pretty Stable
Capital Expenditure Coverage Ratio2.2 M2.5 M2.7 M
Slightly volatile
Debt Ratio0.05890.0623.3203
Slightly volatile
Price Sales Ratio2.983.1479.2 K
Slightly volatile
Asset Turnover1.021.072.5844
Pretty Stable

Ensysce Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11.4 M12.8 M14 M
Slightly volatile
Enterprise Value8.8 M9.9 M10.8 M
Slightly volatile

Ensysce Fundamental Market Drivers

Forward Price Earnings0.9496
Cash And Short Term Investments3.5 M

Ensysce Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ensysce Biosciences Financial Statements

Ensysce Biosciences stakeholders use historical fundamental indicators, such as Ensysce Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ensysce Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ensysce Biosciences' assets and liabilities are reflected in the revenues and expenses on Ensysce Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ensysce Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue182.9 K192 K
Total Revenue6 M6.3 M
Cost Of Revenue8.3 M6.2 M
Stock Based Compensation To Revenue19.1 K20.1 K
Sales General And Administrative To Revenue 1.04  0.99 
Research And Ddevelopement To Revenue 1.25  2.27 
Revenue Per Share 3.43  3.26 
Ebit Per Revenue(1.16)(1.22)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:
How To Invest In Ensysce
Details
Is Ensysce Stock a good investment?
Details
What is Ensysce Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ensysce Biosciences Correlation against competitors.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Ensysce diversify its offerings? Factors like these will boost the valuation of Ensysce Biosciences. Projected growth potential of Ensysce fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ensysce Biosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(6.35)
Revenue Per Share
2.32
Quarterly Revenue Growth
(0.86)
Return On Assets
(1.10)
Return On Equity
(2.94)
Investors evaluate Ensysce Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ensysce Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ensysce Biosciences' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Ensysce Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ensysce Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Ensysce Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY